AstraZeneca revenue and financials
11,960.00 GBpChange from previous close: +0.02%Absolute change: +2.00 GBp
In the fiscal year ended December 2025, AstraZeneca reported revenue of $58.74B (+8.63% year over year). Net income was $10.23B, a net margin of 17.4%.
Fiscal year ending in December. Sources and method on the page Methodology and sources.
At a glance
- Revenue growth
- +8.63%
- 2025 vs 2024
- Net income growth
- +45.34%
- 2025 vs 2024
- Net margin
- 17.4%
- 2024: 13.0%
Financial data
Amounts in millions of USD; per-share values in USD; shares in millions.
| Item | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total revenue | 15,384 | 15,288 | 15,503 | 15,191 | 14,457 | 13,588 | 14,891 | 13,565 | 12,938 | 12,679 | 12,024 | 11,492 |
| Cost of revenue | 2,531 | 2,673 | 3,170 | 2,792 | 2,473 | 2,241 | 2,156 | 3,081 | 2,183 | 2,218 | 2,080 | 2,095 |
| Gross profit | 12,853 | 12,615 | 12,333 | 12,399 | 11,984 | 11,347 | 12,735 | 10,484 | 10,755 | 10,461 | 9,944 | 9,397 |
| Selling, general and administrative | 5,724 | 5,027 | 5,318 | 5,196 | 5,007 | 4,627 | 4,474 | 5,288 | 5,061 | 4,630 | 3,786 | 4,929 |
| Research and development | 3,672 | 3,471 | 3,615 | 3,630 | 3,548 | 3,159 | 3,337 | 3,115 | 3,008 | 2,783 | 2,887 | 2,584 |
| Operating income | 3,609 | 4,272 | 3,347 | 3,662 | 3,508 | 3,608 | 4,962 | 2,106 | 2,746 | 3,115 | 3,341 | 1,954 |
| EBIT | 3,609 | 4,272 | 3,347 | 3,662 | 3,508 | 3,608 | 4,962 | 2,106 | 2,746 | 3,115 | 3,341 | 1,954 |
| EBITDA | 5,193 | 5,638 | 4,113 | 5,211 | 4,897 | 4,892 | 5,249 | 3,923 | 4,025 | 4,370 | 4,233 | 3,180 |
| Interest expense | 435 | 393 | 155 | 434 | 439 | 349 | 139 | 457 | 443 | 413 | 38.0 | 392 |
| Pre-tax income | 2,799 | 3,914 | 2,629 | 3,244 | 3,127 | 3,402 | 1,666 | 1,828 | 2,397 | 2,800 | 897 | 1,652 |
| Income tax | 291 | 833 | 300 | 709 | 679 | 481 | 166 | 395 | 469 | 620 | -62.0 | 274 |
| Net income | 2,507 | 3,080 | 2,326 | 2,533 | 2,450 | 2,916 | 1,500 | 1,429 | 1,927 | 2,179 | 960 | 1,374 |
| Net income to common shareholders | 2,507 | 3,080 | 2,326 | 2,533 | 2,450 | 2,916 | 1,500 | 1,429 | 1,927 | 2,179 | 960 | 1,374 |
| Basic EPS | 1.62 | 1.99 | 1.50 | 1.63 | 1.58 | 1.88 | 0.97 | 0.92 | 1.24 | 1.41 | 0.62 | 0.89 |
| Diluted EPS | 1.61 | 1.97 | 1.48 | 1.62 | 1.57 | 1.87 | 0.96 | 0.91 | 1.23 | 1.40 | 0.61 | 0.88 |
| Average shares (basic) | 1,551 | 1,549 | 1,551 | 1,551 | 1,550 | 1,550 | 1,550 | 1,550 | 1,549 | 1,549 | 1,549 | 1,549 |
| Average shares (diluted) | 1,560 | 1,561 | 1,563 | 1,561 | 1,559 | 1,561 | 1,562 | 1,562 | 1,560 | 1,560 | 1,561 | 1,560 |
| Dividend per share | 1.06 | — | 2.17 | 0.00 | 1.03 | — | 2.10 | 0.00 | 1.00 | — | 1.97 | — |